Stroke · patients with hypertension
CCBs showed no clear difference in stroke compared with ARB (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs may leads to higher congestive heart failure compared with ARB (low certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ARB (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs showed no clear difference in stroke compared with diuretic (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs probably leads to higher congestive heart failure compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with diuretic (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with β‐blocker (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with β‐blocker (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs probably leads to lower stroke compared with β‐blocker (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs showed no clear difference in congestive heart failure compared with β‐blocker (low certainty).
1 finding from 1 review
Systolic blood pressure · People who may be at risk for primary hypertension
2 findings from 1 review
Diastolic blood pressure · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose less than 1000 mg a day (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose between 1000 mg a day and less than 1500 mg a day · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose 1500 mg a day or more (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. 35 years or older (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Secondary outcome: all adverse events · People who may be at risk for primary hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found